Spring til hovednavigation
Spring til søgning
Spring til hovedindhold
Sorter
Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
100%
Overall Survival
82%
Acute Myeloid Leukemia
61%
Non Small Cell Lung Cancer
61%
Progression Free Survival
60%
Malignant Neoplasm
56%
Clinical Trial
55%
Neoplasm
52%
Atrial Fibrillation
45%
Frailty
43%
Personalized Medicine
41%
Cancer Staging
41%
Targeted Therapy
41%
Classical Hodgkin Lymphoma
41%
Pancreas Cancer
41%
Gemcitabine
41%
Mantle Cell Lymphoma
41%
Patient Registry
41%
Quality of Life
39%
Hazard Ratio
38%
International Prognostic Index
34%
Lung Cancer
28%
Heart Disease
26%
Cohort Analysis
23%
Venetoclax
23%
Lenalidomide
23%
Rituximab
23%
Circulating Tumor DNA
22%
Apoplexy
22%
Tumor
22%
Cancer
22%
Somatics
21%
Systematic Review
20%
Homologous Recombination
20%
Immune Checkpoint Inhibitor
20%
Socioeconomic Status
20%
Solid Malignant Neoplasm
20%
Lymphocyte
20%
Gene Expression Profiling
20%
Gene Expression
20%
Induction Chemotherapy
20%
Clustered Regularly Interspaced Short Palindromic Repeat
20%
Cas9
20%
DNA Damage Response
20%
Cisplatin
20%
Clinical Management
20%
Radiation Pneumonia
20%
Protein Expression
20%
Breast Cancer Resistance Protein
20%
Pleura Mesothelioma
20%
Mesothelioma
20%
Esophageal Adenocarcinoma
20%
Brain Ischemia
20%
Mechanical Thrombectomy
20%
Cancer Screening
20%
Chemotherapy
20%
Cancer Therapy
20%
Adverse Event
20%
Hodgkin's Lymphoma
20%
Late Effect
20%
Cross Sectional Study
20%
Aqueous Humor
20%
Diabetic Macular Edema
20%
Vasculotropin
20%
Proteomics
20%
Right Atrium
20%
Sinoatrial Node
20%
Prognostic Factor
20%
Diseases
19%
Multiple Myeloma
17%
Biological Marker
17%
Recurrent Disease
15%
Multivariate Analysis
15%
Proportional Hazards Model
14%
Randomized Clinical Trials
13%
Second Cancer
13%
Leukocyte
13%
Clinical Stage
13%
Preoperative Chemotherapy
13%
Radiation Therapy
13%
Artificial Intelligence
12%
Oncology
12%
Comorbidity
10%
Charlson Comorbidity Index
10%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
10%
Combination Chemotherapy
10%
Allogeneic Stem Cell Transplantation
10%
Recurrence Free Survival
10%
T Cell
10%
Cancer Control
10%
Cell Count
9%
Minimal Residual Disease
9%
Blood Clot Lysis
9%
Cardiovascular Disease
9%
Rebound
9%
Optical Coherence Tomography
8%
Congestive Heart Failure
7%
Hematopoiesis
7%
Attributable Risk
7%
Sex Difference
6%
Keyphrases
Outcome Prediction
48%
Denmark
43%
Privacy Metrics
41%
Synthetic Data Generation
41%
Frailty Score
41%
Classical Hodgkin Lymphoma
41%
Older Patients
41%
Atrial Fibrillation
41%
F1 Score
30%
Clinical Trials
20%
Diffuse Large B-cell Lymphoma (DLBCL)
20%
National Cohort Study
20%
Substantial Clinical Benefit
20%
Late-stage Cancer
20%
Deficiency Detection
20%
Treatment Trajectory
20%
Treatment Lines
20%
Danish National Patient Registry
20%
Systemic Anti-cancer Treatment
20%
Solid Tumors
20%
Tumor Patients
20%
Nab-paclitaxel
20%
Relapsed or Refractory Acute Myeloid Leukemia
20%
Exhaled Breath Biomarkers
20%
CRISPR-Cas9 Knockout
20%
Cisplatin Response
20%
Knockout Screen
20%
Stroke Risk
20%
Female Patients
20%
Male Patients
20%
Rare Germline Variants
20%
Evolutionary Events
20%
Spatial Distribution
20%
Acute Myeloid Leukemia
20%
Prospective Cohort Study
20%
Transient Ischemic Attack
20%
Long-term Fatigue
20%
Linear Autoencoder
20%
Signature Extraction
20%
Interactive Evaluation
20%
CDCA2
20%
Philemon
20%
Privacy-preserving
20%
Definitive Radiation
20%
Information Extraction
20%
Electronic Health Records
20%
Natural Language Processing
20%
Privacy Awareness
20%
Data Synthesis
20%
Louis Pasteur
20%
Myeloid Cancer
20%
Somatic Variant Calling
20%
Mechanical Thrombectomy
20%
Cardiac Events
20%
Acute Ischemic Stroke
20%
Radon Decay
20%
Perioperative Chemotherapy
20%
Afamin
20%
Aqueous Humor
20%
Diabetic Macular Edema
20%
Volume of Fluid
20%
Proteomics
20%
Subretinal Fluid
20%
Anti-VEGF Therapy
20%
Sinoatrial Node
20%
Right Atrium
20%
Irradiation
20%
Non-small Cell Lung Cancer (NSCLC)
20%
Hazard Ratio
20%
Radiation-induced Heart Disease
20%
Synthetic Data
19%
International Prognostic Index
17%
Generation Mechanism
17%
Bidirectional Transformer
15%
Molecular Tumor Board
15%
Positional Variation
15%
Related Entity
15%
Cancer-related
15%
Downstaging
15%
Online Calculator
13%
Delphi Method
13%
Predictive Models
13%
Differential Privacy
13%
Acute Infarction
12%
De Novo Atrial Fibrillation
11%
Lymphoma
10%
Lymphoma Patients
10%
Progression-free Survival
10%
Inter-fraction
10%
Long-course Radiotherapy
10%
Sex Differences
10%
Natural Language Processing Model
10%
Relative Performance
10%
Performance Difference
10%
Junctional Adenocarcinoma
10%
Median Progression-free Survival
10%
Treatment of Recurrence
10%
Anatomic Site
10%
Treatment Characteristics
10%
Reperfusion Therapy
9%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
82%
Chemotherapy
74%
Malignant Neoplasm
72%
Overall Survival
68%
Clinical Trial
66%
Diffuse Large B Cell Lymphoma
58%
Cohort Study
47%
Progression Free Survival
41%
Mantle Cell Lymphoma
41%
Heart Disease
28%
Cardiovascular Disease
26%
Cardiotoxicity
23%
Lenalidomide
23%
Rituximab
23%
Venetoclax
23%
Circulating Tumor DNA
22%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
20%
Pancreas Cancer
20%
Patient Registry
20%
Neoplasm
20%
Esophageal Adenocarcinoma
20%
Ibrutinib
20%
Cancer Staging
20%
Gemcitabine
20%
Solid Malignant Neoplasm
20%
Paclitaxel
20%
Anthracycline
20%
Brain Ischemia
20%
Vasculotropin
20%
Diabetic Macular Edema
20%
Atrial Fibrillation
20%
Non Small Cell Lung Cancer
20%
Remission
18%
Multiple Myeloma
17%
Congestive Heart Failure
17%
Diseases
16%
Survival Rate
10%
Second Cancer
10%
Rigor
10%
Randomized Clinical Trial
10%
Comorbidity
10%
Recurrent Disease
10%
Social Determinants of Health
10%
Minimal Residual Disease
9%
Recurrence Free Survival
8%
Female Genital Tract Cancer
8%
Biological Marker
7%
Clusterin
5%
Edema
5%
Enzyme-Linked Immunosorbent Assay
5%
Cystatin C
5%
Ischemic Heart Disease
5%
Adenocarcinoma
5%
Lactate Dehydrogenase
5%
Lung Cancer
5%
RNA-Sequencing
5%
Postoperative Complication
5%
Dysphagia
5%
Drug Administration
5%
Chimeric Antigen Receptor
5%